Overview

A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)

Status:
Completed
Trial end date:
2010-10-04
Target enrollment:
0
Participant gender:
All
Summary
This study will assess, over a 4-week treatment period, the safety and efficacy of the addition of sitagliptin to metformin in participants with type 2 diabetes mellitus (T2DM) who failed to achieve glycemic control on metformin monotherapy.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Metformin
Sitagliptin Phosphate
Criteria
Inclusion Criteria:

- Participants with T2DM failing metformin monotherapy

- Between the ages of 18 and 79

Exclusion Criteria:

- Participants has a history of type 1 Diabetes Mellitus or ketoacidosis